Budget impact and transferability of cost–effectiveness of DPYD testing in metastatic breast cancer in three health systems

Rositsa Koleva-Kolarova*, Heleen Vellekoop, Matthijs Versteegh, Maureen van Molken, László Szilberhorn, Tamás Zelei, Balázs Nagy, Sarah Wordsworth, Apostolos Tsiachristas

*Corresponding author for this work

Research output: Contribution to journalArticleAcademicpeer-review

2 Citations (Scopus)
7 Downloads (Pure)

Abstract

The cost–effectiveness and budget impact of introducing extended DPYD testing prior to fluoropyrimidine-based chemotherapy in metastatic breast cancer patients in the UK, The Netherlands and Hungary were examined. DPYD testing with ToxNavC was cost-effective in all three countries. In the UK and The Netherlands, the ToxNav strategy led to more quality-adjusted life years and fewer costs to the health systems compared with no genetic testing and standard dosing of capecitabine/5-fluorouracil. In Hungary, the ToxNav strategy produced more quality-adjusted life years at a higher cost compared with no testing and standard dose. The ToxNav strategy was found to offer budget savings in the UK and in The Netherlands, while in Hungary it resulted in additional budget costs.

Tweetable abstract:
The cost–effectiveness and budget impact of extended DPYD testing with ToxNav prior to capecitabine/5-fluorouracil in metastatic breast cancer in the UK, The Netherlands and Hungary were examined. ToxNav was cost-effective in all three countries and budget-saving in the UK and The Netherlands.
Original languageEnglish
Pages (from-to)357-374
Number of pages18
JournalPersonalized Medicine
Volume20
Issue number4
DOIs
Publication statusE-pub ahead of print - 14 Aug 2023

Bibliographical note

Publisher Copyright:
© 2023 Future Medicine Ltd.. All rights reserved.

Fingerprint

Dive into the research topics of 'Budget impact and transferability of cost–effectiveness of DPYD testing in metastatic breast cancer in three health systems'. Together they form a unique fingerprint.

Cite this